首页|JS026及JS026联合JS016注射液在健康受试者中的药代动力学研究

JS026及JS026联合JS016注射液在健康受试者中的药代动力学研究

扫码查看
目的 评价JS026及JS026联合JS016单次静脉输注给药在健康受试者中的耐受性、安全性和药代动力学特征.方法 本研究按随机、双盲、安慰剂对照试验设计.共计入组48例中国健康成年受试者(JS026单剂组32例,JS026联合JS016组16例).以安慰剂为对照,JS026单剂量递增组依次从低剂量向高剂量(30~1 000 mg)序贯进行,联合用药组为JS026 300或600 mg联合JS0161 200 mg静脉输注给药.按试验设计的时间点采集血样.用酶联免疫吸附试验法测定血清中JS026和JS016药物浓度,用WinNonlin 8.2软件计算药代动力学参数,用Power model方法评价给药剂量与血清暴露量的线性关系.结果 本研究共47例受试者完成全部随访,1例受试者因失访退出.单次静脉输注JS02630、100、300、600、1 000 mg 后,Cmax分别为(9.47±1.53)、(33.20±4.95)、(96.10±13.70)、(177.00±22.20)和(353.00±56.70)μg·mL-1,AUC0-∞ 分别为(4 225.00±607.00)、(1.78 × 104±3 268.00)、(5.83 × 104±1 038.00)、(1.07 ×105±152.00)和(1.66 ×105±327.00)μg·h·mL-1,t1/2 为 563~709 h.JS026 300和600 mg单独给药和联合JS016,血清中JS026的Cmax、AUC0-∞基本接近.Power model分析显示,随着JS026剂量增加,Cmax和AUC0-∞近似呈线性增加.安全性和耐受性观察结果显示,JS026在30~1 000 mg单剂给药剂量下,给药后不良事件不随给药剂量增加而增加.JS026单用或联合JS016情况下,与药物相关不良事件大多数为实验室检查值异常和血尿症,无严重不良事件.联合JS016给药相比单剂JS026用药,不良事件发生率无明显上升.结论 JS026的暴露量近似呈线性药代动力学特征,联合JS016给药后JS026暴露量无明显改变.JS026在30~1 000 mg内单剂静脉输注及联合JS016在健康受试者中耐受性、安全性良好.
Pharmacokinetics of JS026 and JS026-JS016 for single intravenous administration in healthy volunteers
Objective To evaluate tolerability,safety and pharmacokinetics of JS026 and JS026-JS016 single dose intravenous infusion in healthy adults.Methods This phase 1,randomized,double-blind,placebo-controlled,dose-escalation study totally included 48 participants:32 healthy subjects were enrolled in JS026 single intravenous infusion groups and 16 healthy subjects were enrolled in JS026-JS016 groups.JS026 was sequentially administered from low dose to high dose(30-1 000 mg),with intravenous infusion of JS026 or placebo in JS026 single-dose groups,and intravenous infusion of JS026-JS016 or placebo in the combination drug groups.Blood was collected according to the time point designed for trial.Serum concentrations of JS026 and JS016 were determined by enzyme linked immunosorbnent assay(ELISA),and pharmacokinetics parameters were calculated by WinNonlin 8.2.The power model method was used to evaluate the linear analysis of dose and drug exposure.Results 47 subjects completed trial and 1 subject lost to follow-up.After a single intravenous injection of JS026 of 30 mg,100 mg,300 mg,600 mg,and 1 000 mg,mean Cmax were(9.47±1.53),(33.20±4.95),(96.10±13.70),(177.00±22.20)and(353.00±56.70)μg·mL-1,respectively;mean AUC0-∞ were(4 225.00±607.00),(1.78 × 104±3 268.00),(5.83 × 104±1 038.00),(1.07 × 105±152.00),(1.66 × 105±327.00)μg·h·mL-1,respectively;mean t1/2 of JS026 were 563-709 h.The Cmax and AUC0-∞ of JS026 were basically similar alone or in combination with JS016.The results of Power model showed that Cmax and AUC0-∞ increased approximately linearly with the increasing dose of JS026.Treatment emergent adverse event was not increasing when dose increased and most of adverse event associated with drugs were abnormal on laboratory tests and haematuria,thus JS026 and JS016 was well tolerated in all groups.Conclusion The single intravenous infusion of JS026 can almost be thought to be a linear relationship between the doses and drug serum exposure.JS016 had no significant effect on serum concentration of JS026 and JS026 was well tolerated and safe in healthy subjects within 30-1 000 mg.

etesevimabJS026JS016tolerabilitysafetypharmacokinetics

田嬿、冶会静、王晶晶、李南洋、马娟、谭希、吴钒、王杰、余姝彦、武晓捷、何金杰、张菁、张文宏

展开 >

复旦大学附属华山医院临床药理研究中心,上海 200040

上海君实生物医药科技股份有限公司,上海 200040

复旦大学附属华山医院感染科国家传染病医学中心上海市传染病与生物安全应急响应重点实验室,上海 200040

埃特司韦单抗 JS026 JS016 耐受性 安全性 药代动力学

上海申康医院发展中心研究型医师创新转化能力培训基金资助项目

SHDC2022CRS004B

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(15)